Quick navigation menu :
  1. Go to content
  2. Go to the main sections menu
  3. Go to the subsections menu
  4. Go to the search engine
  5. Go to the languages menu
  6. Go to the help menu
  7. Go to the slots
  8. Go to contact slot
You are here:
  1. Home
  2. > Press room
  3. > Press releases
  4. > Year 2008
Languages menu :
 

Contacts

Press Relations
Tel. :
(33) 1 53 77 4450
Fax :
(33) 1 53 77 4622
Adress :
174, avenue de France
75013 PARIS
FRANCE
Switchboard :
(33) 1 53 77 4000
Content :

Press releases 2008

Attention(temp en dur) Press releases and press packs are intended to journalists, investors and shareholders.  

May 9, 2008 Plavix® (clopidogrel) in Germany

April 30, 2008 Encouraging first-quarter 2008 results - Further positive Phase III results for eplivanserin

April 28, 2008 U.S. Government accepts $192 million of Sanofi Pasteur H5N1 bulk vaccine antigen for pandemic stockpile

April 22, 2008 Malaria: strong partnerships aiming to benefit patients in Africa

April 15, 2008 Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to Boost Innovation in Vaccine Research for Global Health

April 10, 2008 Information available concerning the Ordinary General Meeting of May 14, 2008

March 26, 2008 NICE Recommends Acomplia® to be included in the NHS Guidance

March 21, 2008 Perioperative Eloxatin®-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases

March 13, 2008 U.S. FDA Licenses DAPTACEL® Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series

March 7, 2008 Filing of the 2007 U.S. Form 20-F and French “Document de Référence” and Annual Financial Report

March 7, 2008 Sanofi-aventis Board of Directors

March 5, 2008 New 300mg loading dose tablet for Plavix® receives positive opinion from the European Committee for Medicinal Products (CHMP)

March 3, 2008 OneWorld Health, Amyris Biotechnologies and Sanofi-aventis Announce Development Agreement for Semisynthetic Artemisinin

February 26, 2008 Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America

February 19, 2008 FDA approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

February 14, 2008 Sanofi-aventis’ SoloSTAR® insulin pen for Lantus and Apidra receives the prestigious GOOD DESIGN Award

February 14, 2008 Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis

February 13, 2008 Sanofi Pasteur Files for European Approval of the First Seasonal Influenza Vaccine Delivered by Intradermal Microinjection

February 12, 2008 2007 earnings ahead of guidance - Sharp rise in proposed dividend

February 12, 2008 Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and "Phage Display Technology"

February 7, 2008 “Pathways of Solidarity” - a book and an exhibition

February 4, 2008 "My child matters": 25 programmes in 16 countries to fight childhood cancers

January 28, 2008 Clexane®/Lovenox® approved in Japan

January 4, 2008 Ambien CR® (zolpidem tartrate extended-release) tablets CIV improved chronic insomnia in patients with co-morbid generalized anxiety disorder

January 3, 2008 Sanofi Pasteur Enters Agreement with Crucell for Next-generation Biologicals against Rabies

© sanofi-aventis 2004-2008 | Legal notice | Update: May 13, 2008